CHMA stock information

Sector:

Healthcare

Description:

Chiasma, Inc., a clinical late-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company develops oral octreotide capsules for adult patients under the MYCAPSSA name, which is in Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Needham, Massachusetts.

Chiasma, Inc. website

Current Price

$3.76

RSI

19.25

Market Capitalization:

237.8M

Beta:

1.257

Volume:

8,250,804

Analyst Target Price:

$ 9.1

Economiic Fair Price:

Report DateMay 05, 2021

QuarterQ1

Forward Dividend N/A

Forward Dividend Rate N/A

Dividend N/A

Dividend Rate N/A

Payout Ratio N/A

Profit MarginN/A

Revenue Per Share TTM0.053

Return On Equity TTM-1.338

2020 Revenue

$ 1.1M

2020 Free Cash Flow

$ -75.7M

-114.33 %

2019 Free Cash Flow

$ -35.3M

-46.57 %

2018 Free Cash Flow

$ -24.1M

1.43 %

2017 Free Cash Flow

$ -24.4M

55.49 %

2016 Free Cash Flow

$ -54.9M

-63.61 %

2015 Free Cash Flow

$ -33.6M

2020 Pre Tax Income

$ -74.7M

Chiasma, Inc.(CHMA)